Oppenheimer Lowers Integra LifeSciences (NASDAQ:IART) to Market Perform

Integra LifeSciences (NASDAQ:IART) was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a report released on Tuesday, MarketBeat.com reports.

A number of other research analysts also recently issued reports on the stock. JMP Securities dropped their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Wells Fargo & Company cut shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $45.00 to $25.00 in a report on Tuesday. Finally, Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $36.80.

Integra LifeSciences Stock Down 0.7 %

Shares of NASDAQ IART opened at $24.91 on Tuesday. Integra LifeSciences has a 52-week low of $22.36 and a 52-week high of $50.78. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The company’s 50 day moving average price is $32.67 and its 200-day moving average price is $38.15. The company has a market capitalization of $1.96 billion, a P/E ratio of 30.01, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. During the same period last year, the company posted $0.74 EPS. The business’s quarterly revenue was down 3.2% on a year-over-year basis. Equities analysts forecast that Integra LifeSciences will post 3.19 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock valued at $273,435,000 after buying an additional 72,294 shares during the period. Capital Research Global Investors grew its position in shares of Integra LifeSciences by 40.1% during the 4th quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after acquiring an additional 1,228,996 shares during the period. Cooke & Bieler LP increased its stake in shares of Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after purchasing an additional 120,410 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Integra LifeSciences by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after purchasing an additional 63,323 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Integra LifeSciences by 19.5% in the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock valued at $55,953,000 after purchasing an additional 238,816 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.